Advertisement
ALNY vs INCY
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Incyte Corporation (INCY) Stock Comparison
Key Takeaways
- ALNY boasts a larger market cap of approximately $44 billion compared to INCY's $20 billion, reflecting stronger growth in its RNAi therapeutics platform.
- Recent revenue surges highlight ALNY's TTR franchise growth at 151% year-over-year, while INCY posted 28% Q4 revenue increase driven by Jakafi and Opzelura.
- INCY shows year-to-date gains of about 2.5%, outperforming ALNY's decline amid short-term volatility in biotech.
- Both stocks exhibit robust one-year returns around 38-40%, underscoring resilience in the biotech sector despite recent market pressures.
- INCY trades at a lower P/E ratio of 15.8 versus ALNY's 142.9, indicating relative value in profitability metrics.
- Pipeline diversification positions ALNY for rare disease expansion, while INCY emphasizes oncology and inflammation stability.
Introduction
Alnylam Pharmaceuticals (ALNY) and Incyte Corporation (INCY) represent key players in the biotechnology sector, focusing on innovative therapies for rare diseases, oncology, and inflammation. This stock comparison evaluates their recent performance, growth drivers, and market positioning amid evolving biotech dynamics. Traders seeking momentum plays and long-term investors eyeing pipeline potential will find value in contrasting ALNY's RNAi leadership against INCY's diversified commercial portfolio. With both delivering strong annual gains, relative performance highlights trade-offs in valuation, revenue trajectories, and risk profiles in the current market environment.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY), a leader in RNA interference (RNAi) therapeutics, develops treatments for rare genetic diseases, particularly transthyretin-mediated amyloidosis (ATTR). In recent market activity, ALNY reported preliminary 2025 net product revenues nearing $3 billion, up 81% year-over-year, propelled by robust TTR franchise growth including Amvuttra launches. The stock, trading around $333 with a $44 billion market cap, has experienced volatility, declining about 16% year-to-date but posting 40% one-year returns. Sentiment reflects optimism for 2026 revenue projections of $4.9-$5.3 billion, tempered by near-term TTR competition and profitability concerns, influencing recent price consolidation.
INCY Overview and Recent Performance
Incyte Corporation (INCY), a biopharmaceutical firm, specializes in small-molecule drugs for oncology, hematology, and inflammation, with flagship products like Jakafi and Opzelura. Recent quarters showed Q4 2025 revenues of $1.51 billion, a 28% increase, and full-year totals at $5.14 billion, up 21%. Trading near $101 with a $20 billion market cap, INCY has gained about 2.5% year-to-date and 38% over the past year, supported by pipeline advancements like positive CHMP opinions and topline data. Performance drivers include diversification beyond Jakafi, though 2026 guidance raised concerns on margins, contributing to modest recent momentum amid sector headwinds.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of over 25 high-performing AI trading bots from its extensive library of hundreds of bots that trade thousands of tickers across diverse strategies. These bots employ AI/ML models for technical and fundamental analysis, generating real-time signals for copy trading in stocks, ETFs, and crypto, with timeframes from 5 minutes to 60 minutes. Top performers boast annualized returns up to +246%, win rates of 54-95%, and profit factors exceeding 25, often outperforming the S&P 500 in sectors like semiconductors and aerospace. Examples include the USAR/SMR/CIFR 60min bot at +246% annualized with 77% win rate, and SOXL 5min at +117%. Varying styles incorporate risk management, hedging, and swing trades. Explore these trending options to enhance your strategy in dynamic markets.
Head-to-Head Comparison
ALNY and INCY both target biotech niches but diverge in models: ALNY's RNAi platform drives rare disease innovation with higher growth potential, while INCY's small-molecule focus yields commercial stability via multiple approved drugs. Growth contrasts ALNY's explosive TTR expansion against INCY's steady oncology/inflammation sales. Recent momentum favors INCY's YTD positivity over ALNY's pullback, though both share strong annual gains. Risks include ALNY's competition and profitability path versus INCY's Jakafi patent cliffs. Sector exposure aligns in biotech, but sentiment leans toward INCY's value at lower multiples amid broader market positioning.
Tickeron AI Verdict
Tickeron’s AI currently favors INCY for its trend consistency, profitability with a P/E under 16, positive YTD performance, and diversified revenue streams reducing near-term volatility risks. While ALNY offers superior growth catalysts like TTR dominance, its elevated valuation and recent downside suggest higher uncertainty. Probabilistic edge tilts to INCY for relative stability in the biotech landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and INCY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- INCY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while INCY’s TA Score has 6 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 6 bearish.
- INCY’s TA Score: 6 bullish, 2 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -0.83% price change this week, while INCY (@Biotechnology) price change was -0.14% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.76%. For the same industry, the average monthly price growth was -2.54%, and the average quarterly price growth was +8.18%.
Reported Earning Dates
ALNY is expected to report earnings on Jul 30, 2026.
INCY is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Biotechnology (-2.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ALNY | INCY | ALNY / INCY | |
| Capitalization | 39.2B | 19.5B | 201% |
| EBITDA | 866M | 1.87B | 46% |
| Gain YTD | -26.204 | -1.149 | 2,280% |
| P/E Ratio | 73.73 | 13.79 | 535% |
| Revenue | 4.29B | 5.36B | 80% |
| Total Cash | 3.01B | 4.02B | 75% |
| Total Debt | 1.27B | 39.4M | 3,231% |
ALNY | INCY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 58 | 74 | |
SMR RATING 1..100 | 14 | 32 | |
PRICE GROWTH RATING 1..100 | 64 | 48 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 33 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (68) in the Biotechnology industry is in the same range as ALNY (89). This means that INCY’s stock grew similarly to ALNY’s over the last 12 months.
ALNY's Profit vs Risk Rating (58) in the Biotechnology industry is in the same range as INCY (74). This means that ALNY’s stock grew similarly to INCY’s over the last 12 months.
ALNY's SMR Rating (14) in the Biotechnology industry is in the same range as INCY (32). This means that ALNY’s stock grew similarly to INCY’s over the last 12 months.
INCY's Price Growth Rating (48) in the Biotechnology industry is in the same range as ALNY (64). This means that INCY’s stock grew similarly to ALNY’s over the last 12 months.
INCY's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALNY (100). This means that INCY’s stock grew similarly to ALNY’s over the last 12 months.
| ALNY | INCY | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 67% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 84% | N/A |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 62% |
| Advances ODDS (%) | 10 days ago 76% | 5 days ago 62% |
| Declines ODDS (%) | 5 days ago 66% | 2 days ago 59% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 72% | 2 days ago 63% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AVGU | 50.70 | 5.00 | +10.94% |
| GraniteShares 2x Long AVGO Daily ETF | |||
| IBLC | 53.88 | 1.06 | +2.01% |
| iShares Blockchain and Tech ETF | |||
| SCHK | 35.94 | 0.29 | +0.81% |
| Schwab 1000 ETF | |||
| VCV | 10.68 | 0.01 | +0.14% |
| INVESCO CALIFORNIA VALUE MUNI Income TRUST | |||
| USSH | 50.42 | -0.01 | -0.03% |
| WisdomTree 1-3 Year Laddered Trsy ETF | |||